T. Rowe Price Investment Management
KMTS

T. Rowe Price Investment Management’s Kestra Medical Technologies KMTS Stock Holding History

T. Rowe Price Investment Management’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,299,391
Closed -$21.5M – 937
2025
Q2 		$21.5M Sell
1,299,391
-972,364
-43% -$21.2M 0.01% 494
2025
Q1 		$56.6M Buy
+2,271,755
New +$52.2M 0.04% 371

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Investment Management's KMTS Position: Q3 2025 in Review

T. Rowe Price Investment Management sold out of Kestra Medical Technologies (KMTS) in Q3 2025, closing a stake of 1,299,391 shares — an estimated $21.5M sold.

T. Rowe Price Investment Management first reported a position in KMTS in Q1 2025 and held it in 2 quarters. The position peaked at $56.6M in Q1 2025. 80 funds tracked by Wall St. Rank hold KMTS as of Q3 2025.

  • T. Rowe Price Investment Management reported no remaining Kestra Medical Technologies position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,299,391 Kestra Medical Technologies shares in Q3 2025, an estimated $21.5M.
  • T. Rowe Price Investment Management first reported a position in Kestra Medical Technologies in Q1 2025 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Kestra Medical Technologies position peaked at $56.6M in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q3 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.